中国实用外科杂志

• 专题笔谈 • 上一篇    下一篇

肝癌系统治疗中肿瘤超进展研究现状

徐    磊,张万广   

  1. 华中科技大学同济医学院附属同济医院肝脏外科中心,湖北武汉 430030
  • 出版日期:2021-03-01 发布日期:2021-03-18

  • Online:2021-03-01 Published:2021-03-18

摘要: 随着肝癌系统治疗的快速发展,靶向治疗、免疫治疗等系统治疗已广泛应用于不可切除肝癌或交界可切除肝癌的转化治疗。肿瘤的超进展是一种肿瘤加速生长的现象,在接受系统治疗的肝癌等实体瘤病人中均有发生,主要与免疫治疗相关。目前,临床上对肝癌中肿瘤超进展的认识不足,缺乏相关的临床研究,尚无法正确评估肿瘤超进展是否发生及严重程度。

关键词: 肿瘤超进展, 系统治疗, 肝癌

Abstract: Recent advance in tumor hyperprogression in systemic therapy of liver cancer        XU Lei, ZHANG Wan-guang.Liver Surgery Center, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Corresponding author:ZHANG Wan-guang, E-mail:wgzhang@
tjh.tjmu.edu.cn
Abstract    With the rapid development of systemic treatment in liver cancer,targeted therapy and immunotherapy have been widely performed in advanced and recurrent liver cancer. Tumor hyperprogression is a phenomenon of accelerated tumor growth,which occurs in patients with solid tumors such as liver cancer who have received systematic treatment,and is mainly related to immunotherapy. At present,the understanding of tumor hyperprogression in liver cancer is insufficient for the lack of relevant clinical studies,so it is difficult to predict the occurrence and severity of tumor hyperprogression.

Key words: hyperprogressive disease, systemic therapy, liver cancer